AIINEWS

AIINEWS

Global intelligence on artificial intelligence and computing

Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work

AIINEWS Editorial Board•startups
05 November, 2026•6 min read
Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work

Executive Briefing

“A new British startup believes that artificial intelligence is the key to speedrunning the slow and”

Key Takeaways

  • 1.A new British startup believes that artificial intelligence is the key to speedrunning the slow and temperamental process of drug design.
  • 2.Potential Sciences plans to build large-scale chemical datasets by using basic principles of physics to simulate interactions between atoms, then small molecules, then complex amino acids and proteins.
  • 3.With that data, it’s betting it can train AI models and prediction systems capable of identifying highly targeted drugs for specific diseases, bypassing costly and time-consuming lab experimentation.

A new British startup believes that artificial intelligence is the key to speedrunning the slow and temperamental process of drug design.

Potential Sciences plans to build large-scale chemical datasets by using basic principles of physics to simulate interactions between atoms, then small molecules, then complex amino acids and proteins. With that data, it’s betting it can train AI models and prediction systems capable of identifying highly targeted drugs for specific diseases, bypassing costly and time-consuming lab experimentation.

“We want molecules that are never going to work in the clinic to fail fast,” Hatem Helal, Potential Science’s founder and CEO, tells WIRED. “That means having better predictors of how they will behave as they interact with human biology.”

The startup, which launched on November 5, says it has seed funding in the tens of millions of dollars from SovAI—the UK government’s AI venture capital fund—and Twin Path Ventures, among other investors. The founders declined to disclose the precise figure or valuation.

If things pan out as Potential Sciences hopes, it could pave the way for the accelerated development of new treatments for all sorts of diseases. By reducing the cost of experimentation, Helal says, the company’s approach could also make it economical for pharmaceutical companies to pursue drugs for rare conditions that have previously gone untreated.

“We want to make it possible to have more bespoke treatments for diseases—this idea that medicines can be one-off molecular combinations that are tailored to your unique human biology,” he says.

The question is whether Potential Sciences will be able to predict how well drug candidates will bind to disease-related proteins as accurately as it hopes, which would require a marked leap forward.

“I’m sure it will be an improvement,” says Peter Wolynes, a professor of chemistry at Rice University. But currently, “the engineering is at the level of the Romans, not of the Renaissance, in terms of how protein engineering is done,” he says.

Industry luminaries like Demis Hassabis, who won the Nobel Prize for Chemistry for his work at Google DeepMind, have long said that advances in AI will eventually lead to momentous scientific breakthroughs, in the same way the technology has recently carved up mathematics. The hope among startups like Potential Sciences is that drug discovery will be one of the first scientific frontiers to be transformed by the technology.

At the moment, a large proportion of AI drug discovery labs are developing models on top of a single public database of 3D atomic structures—the Protein Data Bank—which researchers have expanded over decades with the results of new experiments. The problem, according to Helal, is that the dataset remains too small to train AI models advanced enough to reliably accelerate the search for viable drug candidates.

“Of all the atoms in the universe, there’s around 10 60 ways that you could assemble them into molecules that you could potentially give to a human,” says Helal. “Think of drug discovery as a search problem; it’s about how fast you can navigate and prune that space into promising molecules for a particular disease.”

To address that issue, Potential Sciences is trying to construct far larger datasets made up of synthetic data, produced by simulating interactions between different chemical compounds. From far larger pools of data, the theory goes, the startup will be able to train far more advanced AI models and prediction systems.

Academics see the potential in the simulation-based approach that Potential Sciences has adopted. “If we could calculate accurately the interactions between all molecules in the cell and the fluctuations in their structure we could predict where molecules would bind and that would indeed revolutionize drug development,” says Alan Fersht, an emeritus professor of chemistry at the University of Cambridge who specializes in protein engineering. “I am optimistic that this will eventually happen.”

In receiving investment from SovAI, Potential Sciences joins fellow AI drug discovery companies Basecamp Research and Isomorphic Labs, and materials discovery startup CuspAI.

The UK government established SovAI earlier this year with a mandate to invest in British startups capable of becoming indispensable components of the global AI supply chain, affording the country vital geopolitical leverage. The fund has at its disposal roughly $800 million and the ability to offer its portfolio companies access to the UK’s national AI supercomputer.

“Coming at drug discovery from a physics angle—the physics of chemistry—sets [Potential Sciences] apart from other companies,” says Joséphine Kant, head of ventures at SovAI, who has joined the startup’s board as part of the investment. “Giving them access to computing resources, they can do this work at a scale that would be very difficult otherwise for a small startup.”

However, AI drug discovery is a crowded market. Even with a leg up from the UK government, Potential Sciences will face steep competition from a multitude of entrepreneurs and academics racing to solve the same bottlenecks from varying angles of approach.

Nor does the ability to more quickly identify promising drug candidates eliminate the cost and time required to test their safety and efficacy, meaning new treatments will continue to take a long time to come to market, regardless of advances in AI. “The cost of designing a drug is nothing compared to figuring out what it will do to mice; to really sick patients; to normal people,” says Wolynes. “In some sense, it’s not the rate-limiting phenomenon.”

As the field progresses, startups like Potential Sciences will also have to contend with the prospect that technologies able to identify effective treatments could be abused to develop highly dangerous chemicals, too. “If we can design tools that perfectly minimize toxicity, it’s a bit flip to maximize it as well,” Helal says.

Potential Sciences doesn’t yet have all the answers. The startup hasn’t settled on a way to generate revenue from the various technologies it’s developing nor decided whether to make its models freely available, given the potential for misuse. But Helal is convinced that there are few more worthwhile problems to try to remedy with AI.

“There have been many waves of promising breakthroughs that don’t quite have an impact in drug discovery,” says Helal. “It’s a fundamental, high-impact problem for us to try and solve.”

Comments

Back to top

Content and editorial synthesis copyright by AIINEWS Editorial Board
Share this intelligence report:
Expanded Perspectives & Intelligence

Related Dispatches & Deep Dives

Curated 8 specialized reports
Ollie, a privacy-focused AI assistant, is shutting down

Ollie, a privacy-focused AI assistant, is shutting down

Ollie, a startup whose mission was to deliver an AI assistant that respected its users’ privacy, says that it will be shutting down in a week. Bill Lennon, the company’s co-founder and CEO, took to X on Friday to deliver the news, noting that the app will officially shut down on November 6. “I’m really proud of what we accomplished,” Lennon said.

2 min read7,172
OpenAI missed funding plan, Anthropic filed to go public: money for AI is starting to be picky

OpenAI missed funding plan, Anthropic filed to go public: money for AI is starting to be picky

## **OpenAI raising capital did not go as planned** According to the Wall Street Journal, OpenAI initially aimed to raise about 30 billion USD in the new round, but now only has about 11 billion USD in commitments, less than half. Some large investors appear quite indifferent. The valuation of this round is 1,250 billion USD, lower than the 1,400 billion USD that OpenAI once hoped to achieve.

6 min read8,898
Salesforce’s M&A spree continues with a reported $375M deal for defense tech startup Rune

Salesforce’s M&A spree continues with a reported $375M deal for defense tech startup Rune

Salesforce has agreed to acquire Rune Technologies, a startup that builds AI software to help the U.S. military predict supply needs and manage logistics from the field, for $375 million in cash and stock, Resilience Media reported. The acquisition underscores Salesforce’s push into defense tech through Missionforce, its business unit serving national security and defense agencies.

2 min read7,792
Orbital Matter 3D printed the first rigid beam in the vacuum of space

Orbital Matter 3D printed the first rigid beam in the vacuum of space

A satellite built by the German startup Orbital Matter satellite 3D printed a half-meter long beam out of a custom plastic material, in what executives called a first for a free-flying spacecraft in orbit, and a step toward constructing large structures in space. The company’s small satellite, Replicator-2, was launched on a SpaceX rideshare mission this summer, with four of the company’s 3D printers onboard. Each printer can create a rigid, cylindrical beam by extruding coils of resin that are cured by an ultraviolet light, which the company analogizes to cement and water.

3 min read8,373
Build a semantic layer for agentic AI with EDB Postgres AI and Amazon Bedrock AgentCore

Build a semantic layer for agentic AI with EDB Postgres AI and Amazon Bedrock AgentCore

In this post, we show how to build a semantic layer for agentic AI using EDB Postgres AI. We run a Strands Agents agent on Amazon Bedrock AgentCore that queries the layer to answer customer 360 (C360) questions. Earlier posts in this series built the same C360 pattern with Stardog’s knowledge graph, Denodo’s data virtualization platform, AtScale’s dimensional model, and Strategy Mosaic’s linked models.

20 min read7,332
Almost no one uses AI agents to book their Uber, company says

Almost no one uses AI agents to book their Uber, company says

Very few people are using personal AI agents to order Ubers, apparently. On the transportation giant’s third-quarter earnings call on Wednesday, the company said that only four rides were ordered through an AI agent during its busiest week in October: the week of Halloween. While more people used an AI agent to order food through its delivery service, Uber Eats, the volume was still fairly small compared to the overall number of trips.

3 min read7,247

Explore AIINEWS Intelligence Vault

Over 2,000 in-depth dispatches structured across 18 specialized tech & AI categories.

Browse all 18 categories